Nanoparticulate delivery systems for antiviral drugs

Antiviral Chemistry and Chemotherapy

Volumn 21, Issue 2, 2010, Pages 53-70

  Lembo, David ^a   Cavalli, Roberta ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACICLOVIR; AMPRENAVIR; ANTIVIRUS AGENT; ATAZANAVIR; CYCLODEXTRIN; DELAVIRDINE; DENDRIMER; DOXORUBICIN; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FOMIVIRSEN; GANCICLOVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; MICROSPHERE; NANOCRYSTAL; NANOPARTICLE; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; SOLID LIPID NANOPARTICLE; STAVUDINE; UNINDEXED DRUG; ZIDOVUDINE;

ANTIVIRAL THERAPY; BLOOD BRAIN BARRIER; CROSS LINKING; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; EMULSION; HEPATITIS; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEN BOND; INFLUENZA; INNATE IMMUNITY; MACROPHAGE; MICELLE; MICROEMULSION; NANOMEDICINE; NANOTECHNOLOGY; PATIENT COMPLIANCE; POLYMERIZATION; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; RETINITIS; REVIEW; RNA INTERFERENCE; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR TARGETED THERAPY; NANOPARTICLES; NANOTECHNOLOGY; VIRUS DISEASES;

EID: 78751681687     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1684     Document Type: Review

References (119)

1. Milroy D, Featherstone J. Antiviral market overview. Nat Rev Drug Discov 2002; 1:11-12.
2. Roehr B. Fomivirsen approved for CMV retinitis. J Int Assoc Physicians AIDS Care 1998; 4:14-16.
3. Amidon GL, Lennernas H, Shah VP, Crison JR. A Theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12:413-420.
4. Williams GC, Sinko PJ. Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev 1999; 39:211-238.
5. Sharma P, Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev 2010; 62:491-502.
6. Emery VC. Progress in understanding cytomegalovirus drug resistance. J Clin Virol 2001; 21:223-228.
7. Fridland A, Connelly MC, Robbins BL. Cellular factors for resistance against antiretroviral agents. Antivir Ther 2000; 5:181-185.
8. Liaw YF. The current management of HBV drug resistance. J Clin Virol 2005; 34 Suppl 1:S143-S146.
9. Arshady R, Kono K (Editors). Smart nanoparticles in nanomedicine - the MML series. Vol 8. London: Kentus Books 2006.
10. Sosnik A, Amiji M. Nanotechnology solutions for infectious diseases in developing nations. Adv Drug Deliv Rev 2010; 62:375-377.
11. Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: a review on formulating technology, types and applications toward targeted drug delivery. Nanomedicine 2010; 6:9-24.
12. Ketzinel-Gilad M, Shaul Y, Galum E. RNA interference for antiviral therapy. J Gene Med 2006; 8:933-950.
13. Kumar P, Sood V, Vyas R, Gupta N, Banerjea AC, Khanna M. Potent inhibition of influenza virus replication with novel siRNA-chimeric-ribozyme constructs. Antiviral Res 2010; 87:204-212.
14. Subramanya S, Kim SS, Abraham S, et al. Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production. J Virol 2010; 84:2490-2501.
15. Singh SK. RNA interference and its therapeutic potential against HIV infection. Expert Opin Biol Ther 2008; 8:449-461.
16. Huang DD. The potential of RNA interference-based therapies for viral infections. Curr HIV/AIDS Rep 2008; 5:33-39.
17. DeVincenzo J, Lambkin-Williams R, Wilkinson T. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A 2010; 107:8800-8805.
18. Tiemann K, Rossi JJ. RNAi-based therapeutics - current status, challenges and prospects. EMBO Mol Med 2009; 1:142-151.
19. Hillaireau H, Couvreur P. Nanocarriers' entry into the cells: relevance to drug delivery. Cell Mol Life Sci 2009; 66:2873-2896.
20. Wong HL, Chattopadhyay N, Wu XY, Bendayan R. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev 2010; 62:503-517.
21. Strain MC, Letendre S, Pillai SK, et al. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol 2005; 79:1772-1788.
22. Pillai SK, Good B, Pond SK, et al. Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. J Virol 2005; 79:1734-1742. (Pubitemid 40459119)
23. Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV and their role in viral persistence. Curr HIV Res 2008; 6:388-400.
24. Chan LMS, Lowes S, Hirst BH. The ABCs of drug transport in the intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 2004; 21:25-51. (Pubitemid 38050202)
25. Salama NN, Scott KR, Eddington ND. DM27, an enaminone, modifies the in vitro transport of antiviral therapeutic agents. Biopharm Drug Dispos 2004; 25:227-236.
26. Yang ZG, Meng H, Zhang X, et al. [Effect of quercetin on the acyclovir intestinal absorption]. Beijing Da Xue Xue Bao 2004; 36:309-312. Chinese.
27. Torchilin V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm 2009; 71:431-444.
28. Riehemann K, Scheider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine - challenge and perspectives. Angew Chem Int Ed Engl 2009; 48:872-897.
29. Lara HH, Ayala-Nuñez NV, Ixtepan-Turrent LL, Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology 2010; 8:1-10.
30. Elechiguerra JL, Burt JL, Morones JR, et al. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology 2005; 3:6-12.
31. Lu L, Sun RW, Chen R. Silver nanoparticles inhibit hepatitis B virus replication. Antivir Ther 2008; 13:253-262.
32. Sun L, Singh AK, Vig K, Pillai SR, Singh SR. Silver nanoparticles inhibit replication of respiratory syncytial virus. J Biomed Nanotechnol 2008; 4:149-158.
33. Rogers JV, Parkinson CV, Choi YW, Speshock JL, Hussain SL. A preliminary assessment of silver nanoparticles inhibition of monkeypox virus plaque formation. Nanoscale Res Lett 2008; 3:129-133.
34. Baram-Pinto D, Shukla S, Perkas N, Gedanken A, Sarid R. Inhibition of herpes simplex virus type 1 infection by silver nanoparticles capped with mercaptoethane sulfonate. Bioconjug Chem 2009; 20:1497-1502.
35. Ruenraroengsak P, Cook JM, Florence AT. Nanosystem drug targeting: facing up to complex realities. J Control Release 2010; 141:265-276.
36. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumour vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65:271-284.
37. Gupta U, Kompella U. Nanotechnology in drug delivery. New York: Taylor & Francis 2006.
38. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 1996; 13:1838-1845.
39. Sanvicens N, Marco PM. Multifunctional nanoparticles-properties and prospects for their use in human medicine. Trends Biotechnol 2008; 26:425-432.
40. Kim SI, Shin D, Lee H, et al. Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. J Hepatol 2009; 50:479-488.
41. Mishra V, Mahor S, Rawat A, et al. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target 2006; 14:45-53.
42. Clayton R, Ohagen A, Nicol F, et al. Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes. Antiviral Res 2009; 84:142-149.
43. Kim SS, Peer D, Kumar P, et al. RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther 2010; 18:370-376.
44. Feng M, Cai Q, Shi X, Huang H, Zhou P, Guo X. Recombinant high-density lipoprotein complex as a targeting system of nosiheptide to liver cells. J Drug Target 2008; 16:502-508. (Pubitemid 352015819)
45. Feng M, Cai Q, Huang H, Zhou P. Liver targeting and anti-HBV activity of reconstituted HDL-acyclovir palmitate complex. Eur J Pharm Biopharm 2008; 68:688-693. (Pubitemid 351318196)
46. Zhou S, Sun J, Sun L, et al. Preparation and characterization of interferon-loaded magnetic biodegradable microspheres. J Biomed Mater Res B Appl Biomater 2008; 87:189-196.
47. Mahajan SD, Roy I, Xu G, et al. Enhancing the delivery of anti retroviral drug 'saquinavir' across the blood brain barrier using nanoparticles. Curr HIV Res 2010; 8:396-404.
48. Pollock S, Dwek RA, Burton DR, Zitzman N. N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery. AIDS 2008; 22:1961-1969.
49. Chiellini EE, Chiellini F, Solaro R. Bioerodible polymeric nanoparticles for targeted delivery of proteic drugs. J Nanosci Nanotechnol 2006; 6:3040-3047. (Pubitemid 44579980)
50. Gagné JF, Désormeaux A, Perron S, Tremblay MJ, Bergeron MG. Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim Biophys Acta 2002; 1558:198-210. (Pubitemid 34081181)
51. Düzgünes N, Pretzer E, Simões S, et al. Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells. Mol Membr Biol 1999; 16:111-118.
52. Bergamaschi A, Pancino G. Host hindrance to HIV-1 replication in monocytes and macrophages. Retrovirology 2010; 7:31.
53. Gunaseelan S, Gunaseelan K, Deshmukh M, Zhang X, Sinko PJ. Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs. Adv Drug Deliv Rev 2010; 62:518-531.
54. Schäfer V, Von Briesen H, Andreesen R, et al. Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting. Pharm Res 1992; 9:541-546.
55. Zhang X, Jin X, Plummer MR, et al. Endocytosis and membrane potential are required for HeLa cell uptake of R.I.-CKTat9, a retro-inverso Tat cell penetrating peptide. Mol Pharm 2009; 6:836-848.
56. Sosnik A, Chiappetta D, Carcaboso A. Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead. J Control Release 2009; 138:2-15.
57. Gregoriadis G. Overview of liposomes. J Antimicrob Chemother 1991; 28:39-48.
58. Gupta U, Jain N. Non-polymeric nano-carriers in HIV/ AIDS drug delivery and targeting. Adv Drug Deliv Rev 2010; 62:478-490.
59. Pavelić Z, Škalko-Basnet N, Filipović- Grčić J, Martinac A, Jalšenjak M. Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir. J Control Release 2005; 106:34-43.
60. Thitinan S, McConville JT. Interferon alpha delivery systems for the treatment of hepatitis C. Int J Pharm 2009; 369:121-135.
61. Bochot A, Couvreur P, Fattal E. Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog Retin Eye Res 2000; 19:131-147.
62. Peira E, Trotta M, Carlotti ME, Gallarate M, Chirio D. Elastic positively-charged liposomes for topical administration of acyclovir. J Drug Deliv Sci Technol 2007; 17:321-324.
63. Law SL, Huang KJ, Chiang CH. Acyclovir-containing liposomes for potential ocular delivery: corneal penetration and absorption J Control Release 2000; 63:135-140.
64. Chetoni P, Rossi S, Burgalassi S, et al. Comparison of liposome encapsulated acyclovir with acyclovir ointment: ocular pharmacokinetics in rabbits. J Ocul Pharmacol Ther 2004; 20:169-177.
65. Fang JY, Hong CT, Chiu WT, et al. Effect of liposomes and niosomes on skin permeation of enoxacin. Int J Pharm 2001; 219:61-72.
66. Mukherjee B, Patra B, Layek B, et al. Sustained release of acyclovir from nano-liposomes and nano-niosomes: an in vitro study. Int J Nanomedicine 2007; 2:213-225.
67. Attia IA, El-Gizawy SA, Fouda MA, Donia AM. Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. AAPS PharmSciTech 2007; 8:E106.
68. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007; 24:1-16.
69. Nagasaki Y, Yasugy K, Yamamoto Y, et al. Sugar-installed block copoloimer micelles: their preparation and specific interaction with lectin molecules. Biomacromolecules 2001; 2:1067-1070.
70. Jin Y, Xin R, Ai P, et al. Cholesteryl derivatives of antiviral nucleoside analogues: synthesis, properties and the vesicle formation. Int J Pharm 2008; 350:330-337.
71. Jin Y, Tong L, Ai P, et al. Self-assembled drug delivery systems: 1. Properties and in vitro/in vivo behavior of acyclovir self-assembled nanoparticles (SAN). Int J Pharm 2006; 309:199-207.
72. Conti B, Bucalo C, Giannovola C, et al. Biodegradable microspheres for the intravitreal administration of acyclovir: in vitro/in vivo evaluation. Eur J Pharm Sci 1997; 5:287-293.
73. Martinez-Sancho C, Herrero-Vanrell R, Negro S, et al. Study of gamma-irradiation effects on aciclovir poly(d,llactic-co-glycolic) acid microspheres for intravitreal administration. J Control Release 2004; 99:41-52. (Pubitemid 39165732)
74. Martinez-Sancho C, Herrero-Vanrell R, Negro S, et al. Vitamin A palmitate and acyclovir biodegradable microspheres for intraocular sustained release. Int J Pharm 2006; 326:100-106.
75. Rokhade AP, Patil SA, Aminabhavi TM. Synthesis and characterization of semi-interpenetrating polymer network microspheres of acrylamide grafted dextran and chitosan for controlled release of acyclovir. Carbohydr Polym 2007; 67:605-613.
76. Dhaliwal S, Jain S, Singh P, et al. Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation. AAPS J 2008; 10:322-330.
77. Tao Y, Lu Y, Sun Y, et al. Development of mucoadhesive microspheres of acyclovir with enhanced bioavailability. Int J Pharm 2009; 378:30-36.
78. de Jalon EG, Blanco-Prìeto MJ, Ygartua P, Santoyo S. Topical application of acyclovir-loaded microparticles: quantification of the drug in porcine skin layers. J Control Release 2001; 75:191-197.
79. Stulzer HK, Lacerda L, Tagliari MP, et al. Synthesis and characterization of cross-linked chitosan microspheres for controlled release of acyclovir. Carbohydr Polym 2008; 73:490-496.
80. Stulzer HK, Tagliari MP, Parize AL, et al. Evaluation of cross-linked chitosan microparticles containing acyclovir obtained by spray-drying. Materials Science and Engineering: C 2009; 29:387-392.
81. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006; 307:93-102.
82. Zimmer A. Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers. Methods 1999; 18:286-295.
83. Hillaireau H, Le Doan T, Besnard M, Chacun H, Janin J, Couvreur P. Encapsulation of antiviral nucleotide analogues azidothymidine-triphosphate and cidofovir in poly(isobutylcyanoacrylate) nanocapsules. Int J Pharm 2006; 324:37-42.
84. Elshafeey AH, Kamel AO, Awad GAS. Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. Colloids Surf B Biointerfaces 2010; 75:398-404.
85. Gasco MR, inventor. Method for producing solid lipid mirospheres having narrow distribution. 1993 US patent 5,250,236. 1993.
86. Müller RH, Lucks JS. Arzneistoffträger aus festen Lipidteilchen, Feste Lipidnanosphären (SLN). [Medication vehicles made of solid lipid particles (solid lipid nanospheres - SLN)]. European patent 0605497. 1993.
87. Gasco MR. Solid lipid nanoparticles for drug delivery. Pharm Technol Eur 2001; 13:32-41.
88. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of art. Eur J Pharm Biopharm 2000; 50:161-177.
89. Lukowski G, Pflegel P. Electron diffraction of solid lipid nanoparticles loaded with aciclovir. Pharmazie 1997; 52:642-643.
90. Zhang X, Miao J, Li M, et al. Solid lipid nanoparticles loading adefovir dipivoxil for antiviral therapy. J Zhejiang Univ Sci 2008; 9:506-510.
91. Merodio M, Arnedo A, Renedo MJ, Irache JM. Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties. Eur J Pharm Sci 2001; 12:251-259.
92. Arnedo A, Irache JM, Merodio M, et al. Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide. J Control Release 2004; 94:217-227.
93. Zwiorek K, Bourquin C, Winter G, Endres S, Hartmann G, Coester C. Delivery by cationic gelatin nanoparticles strongly increases the immunomodulatory effects of CpG oligonucleotides. Pharm Res 2008; 25:551-556.
94. Gajbhiye V, Palanirajan VK, Tekade RK, et al. Dendrimers as therapeutic agents: a systematic review. J Pharm Pharmacol 2009; 61:989-1003.
95. Salamonczyk GM. Acyclovir terminated thiophosphate dendrimers. Tetrahedron Lett 2003; 44:7449-7753.
96. Luganini A, Giuliani A, Pirri G, Pizzuto L, Landolfo S, Gribaudo G. Peptide-derivatized dendrimers inhibit human cytomegalovirus infection by blocking virus binding to cell surface heparan sulfate. Antiviral Res 2010; 85:532-540.
97. Rupp R, Rosenthal SL, Stanberry LR. VivaGel (SPL7013 gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine 2007; 2:561-566.
98. O'Loughlin J, Millwood IY, McDonald HM, et al. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, Phase I study. Sex Transm Dis 2010; 37:100-104.
99. Ghosh PK, Majithiya RJ, Umrethia ML, Murthy RS. Design and developement of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability. AAPS PharmSciTech 2006; 7:77.
100. Peira E, Chirio D, Carlotti ME, Spagnolo R, Trotta M. Formulation studies of microemulsions for topical applications of acyclovir. J Drug Deliv Sci Technol 2009; 19:191-196.
101. Coviello T, Matricardi P, Marianecci C, Alhaique F. Polysaccharide hydrogels for modified release formulations. J Control Release 2007; 119:5-24. (Pubitemid 46561537)
102. Feeney M, Casadei MA, Matricardi P. Carboxymethyl derivative of scleroglucan: a novel thermosensitive hydrogel forming polysaccharide for drug delivery applications. J Mater Sci Mater Med 2009; 20:1081-1087.
103. Ferruti P, Ranucci E, Cavalli R, Trotta F, inventors; Hyperbranched polymers based on cyclodextrins and poly(amidoamines) for the controlled release of insoluble drugs. European patent PCT EP 004624. 2008.
104. Luengo J, Aranguiz T, Sepulveda J, Von Plessig C. Preliminary pharmacokinetic study of different preparations of acyclovir with beta-cyclodextrin. J Pharm Sci 2002; 91:2593-2598.
105. Nicolazzi C, Venare V, La Faou A. In vitro antiviral efficacy of the ganciclovir complexed with beta-cyclodextrin on human cytomegalovirus clinical strains. Antiviral Res 2002; 54:121-127.
106. Bencini M, Ranucci E, Ferruti P, et al. Preparation and in vitro evaluation of the antiviral activity of the acyclovir complex of a beta-cyclodextrin/poly(amidoamine) copolymer. J Control Release 2008; 126:17-25.
107. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev 1998; 98:2045-2076.
108. Dubes A, Degobert G, Fessi H. Synthesis and characterization of sulfated amphiphilic alpha-, beta-, gamma-cyclodextrins: application to the complexation of acyclovir. Carbohydr Res 2003; 338:2185-2193.
109. Cavalli R, Donalisio M, Civra A, et al. Enhanced antiviral activity of acyclovir loaded into beta-cyclodextrin-poly(4-acryloylmorpholine) conjugate nanoparticles. J Control Release 2009; 137:116-122.
110. Ghera BB, Perret F, Chevalier Y, Parrot-Lopez H. Novel nanoparticles made from amphiphilic perfluoroalkyl alphacyclodextrin derivatives: preparation, characterization and application to the transport of acyclovir. Int J Pharm 2009; 375:155-162.
111. Trotta F, Cavalli R. Characterization and applications of new hyper-cross-linked cyclodextrins. Compos Interfaces 2009; 16:39-48.
112. Swaminathan S, Pastero L, Serpe L, et al. Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity. Eur J Pharm Biopharm 2010; 74:193-201.
113. Swaminathan S, Vavia P, Donalisio M, et al. Characterization of antiviral activity of acyclovir-loaded carboxylated nanosponges. 2nd Italian Cyclodextrin Symposium. 3-5 May 2009, Asti, Italy. Abstract P8.
114. Cavalli R, Trotta F, Tumiatti W. Cyclodextrin-based nanosponges for drug delivery. J Incl Phenom Macrocycl Chem 2006; 56:209-213.
115. Van Eerdenbrugh B, Froyen L, Martens JA. Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. Int J Pharm 2007; 338:198-206.
116. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing approach for poorly-water-soluble compounds. Eur J Pharm Sci 2003; 18:113-120.
117. Aillon KL, Xie Y, El-Gendy N, Berkland CJ, Forrest ML. Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv Drug Deliv Rev 2009; 61:457-466.
118. Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. Science 2006; 311:622-627.
119. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 2008; 3:133-149.